Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecasermin treatment for glucose metabolism and inflammation in cystic fibrosis
2011-002719-27Phase 2Terminated
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
- Start
- Mar 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mecasermin in cystic fibrosis (CF), sponsored by Azienda Ospedaliero-Universitaria di Parma. Primary endpoints: Change in area under the curve for blood glucose concentration, Change in area under the curve for insulin and 2 more. Started Mar 2012; status: terminated.
02
Drugs
mecasermin
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2011-002719-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002719-27.